FRAMINGHAM (09/24/2003) - Dharmacon Inc. has inked a deal with Abbott Laboratories Inc. to collaborate on an siRNA (small interfering RNA) library covering 4,000 genes to identify potential drug targets for Abbott's key therapeutic areas. "After evaluating the many methodologies available for building this large library, we selected Dharmacon as our partner because their approach of direct chemical synthesis provides a highly effective and cost-efficient method for building a large collection of siRNAs," said Abbott's Stephen Fesik, divisional vice president of cancer research, in a press release. "This siRNA library will allow us to rapidly identify new targets in key therapeutic areas, and Dharmacon's SMART algorithms and 2'-ACE chemistry provide a high success rate for gene silencing." This comes on the heels of other recent Dharmacon deals, including two with Exelixis Inc. and Agilent Technologies Inc.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.